BlossomHill Therapeutics Inc. (BLSM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 0.3% FCF Margin ($13.5M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While BLSM currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.98) and Max Pain ($15.97) forces dealer call-delta covering toward $29.39.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
BlossomHill Therapeutics Inc. (BLSM) dropped -7.59% to $15.21, trading at 15% of its 52-week range ($12.93 – $27.99). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
BlossomHill Therapeutics achieved major de-risking milestones with the C797S lung cancer indication as a strategic beachhead. Learn why BLSM stock is a buy.
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative sm
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BLSM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BLSM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, BlossomHill Therapeutics Inc. (BLSM) ranks #450 by composite RQD confidence (46/100, grade D) and #459 by equity capitalization ($483.4M). Within this direct 5-issuer industry benchmark cohort, BLSM leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. BLSM currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BLSM
ACTIVE
BlossomHill Therapeutics Inc. | D | 46/100 | — | — | — | -7.59% | $483.4M | Benchmark Subject |
| MNPR Monopar Therapeutics Inc. | E | 31/100 | — | — | -17.4% | -2.02% | $482.7M | /mnpr-vs-blsm → |
| FTH Faeth Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | -2.34% | $484.5M | /fth-vs-blsm → |
| EOLS Evolus Inc. | E | 21/100 | — | 66.3% | -35.0% | -1.51% | $496.7M | /eols-vs-blsm → |
| CTMX CytomX Therapeutics Inc. | E | 20/100 | — | — | -20.5% | -2.97% | $499.0M | /ctmx-vs-blsm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), BlossomHill Therapeutics Inc. (BLSM) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BLSM closed FY2025 with $163.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $163.0M | — |
As of 2026-11-01, BlossomHill Therapeutics Inc. (NASDAQ: BLSM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $15.21 (-7.59% 1D, market cap $483.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BLSM ranks #450 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLSM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MNPR (Monopar Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M) and FTH (Faeth Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $484.5M). Among the 5-stock peer group, BLSM leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).
Per BLSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001839970), BlossomHill Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $163.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BLSM last traded at $15.21 (-7.59% on volume of 98,961 shares), positioning the stock -19.86% below its 50-day simple moving average ($18.98) and -17.83% below its 200-day simple moving average ($18.51). Across its 52-week range of $12.93 to $27.99, BLSM sits at the 15.1% percentile with a 14-day RSI of 37.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.31 to $17.11).
Why BLSM Stock dropped -7.59% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.